EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster
Executive Summary
With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.
You may also be interested in...
EMA Defines Actions For Using CAR-T Registries For Regulatory Evaluation
A multi-stakeholder EU workshop has helped identify how patient registries can support the benefit-risk evaluation of CAR-T cell therapies, given the challenges posed by these products, not least the need for the long-term follow up of treated patients.
Keep Us In The Loop: EMA Clarifies Expectations Following PRIME Kick-Off Meetings
New guidance from the European Medicines Agency explains how sponsors that have drugs in its priority medicines scheme should interact with its experts and committees.
EU CAR-T Race Tightens After Yescarta Reverts To Standard Review
Kite and Novartis are vying to be the first company to have a CAR-T therapy approved in the EU. Both companies are hoping to be able to treat patients with r/r DLBCL.